Prospecitve study of radiotherapy without surgery after AC followed by weekly paclitaxel and trastuzumab for inflammatory breast cancer with HER2 over expressio
Phase 2
- Conditions
- Inflammatory breast cancer
- Registration Number
- JPRN-UMIN000000513
- Lead Sponsor
- Saitama Breast Cancer Clinical Study Group (SBCCSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. severe complication 2. suspicious of infection 3. past history of allergic reaction to cremophor EL (polyoxyethylated castor oil) or polysorbate 4. pregnant or lactating women 5. doctor's decision for exclusion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method TTP (Time To Progression)
- Secondary Outcome Measures
Name Time Method Overall survival Toxicity Clinical response rate Pathological response rate